Assessing the immunogenic and protective potential of different viral vector regimes, in the mouse model of tuberculosis infection

Assessing the immunogenic and protective potential of different viral vector regimes, in the mouse model of tuberculosis infection

Detalles Bibliográficos
Main Authors:	Stylianou, E, Betts, G, Dicks, M, Griffiths, K, Poyntz, H, Mcshane, H
Formato:	Conference item
Publicado:	2011

Títulos similares

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
por: Betts, G, et al.
Publicado: (2012)

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
por: Griffiths, K, et al.
Publicado: (2013)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
por: Gareth Betts, et al.
Publicado: (2012-01-01)

Th1/Th17 cell induction following vaccination with the novel tuberculosis vaccine MVA85A and their role in Mycobacterium tuberculosis challenge
por: Griffiths, K, et al.
Publicado: (2011)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
por: Stylianou, E, et al.
Publicado: (2015)

Evaluation of immunological mechanisms induced by Mycobacterium avium exposure and the effect upon pre-existing BCG immunity
por: Poyntz, H, et al.
Publicado: (2011)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.
por: Poyntz, H, et al.
Publicado: (2014)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb).
por: Marsay, L, et al.
Publicado: (2013)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis
por: Poyntz, H, et al.
Publicado: (2014)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)
por: Marsay, L, et al.
Publicado: (2013)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
por: Christopher J. De Voss, et al.
Publicado: (2025-02-01)

Viral vector delivery of Env trimer immunogens
por: Parks CL, et al.
Publicado: (2012-09-01)

Uncovering the mechanisms of adenovirus vector immunogenicity
por: Dicks, M, et al.
Publicado: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado: (2013)

Viral vectors as vaccine platforms: from immunogenicity to impact
por: Ewer (nee Russell), K, et al.
Publicado: (2016)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado: (2013)

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
por: Biswas, S, et al.
Publicado: (2011)

Evaluation of the immunological mechanisms induced by mycobacteria and the potential effect this may have on immunity induced by tuberculosis vaccines
por: Poyntz, HC
Publicado: (2012)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
por: Mcshane, H, et al.
Publicado: (2001)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado: (2013)

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
por: Sumi Biswas, et al.
Publicado: (2011-01-01)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
por: Dicks, M, et al.
Publicado: (2011)

Immunogenicity and Protective Efficacy of a Recombinant Pichinde Viral-Vectored Vaccine Expressing Influenza Virus Hemagglutinin Antigen in Pigs
por: Sushmita Kumari, et al.
Publicado: (2022-08-01)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-riming and boosting with adenovirus or protein based vaccines
por: Dean, G, et al.
Publicado: (2014)

Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against Chikungunya virus
por: López-Camacho, C, et al.
Publicado: (2019)

Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
por: Aiquan Chang, et al.
Publicado: (2022-02-01)

Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus
por: César López-Camacho, et al.
Publicado: (2019-04-01)

Protection by Persuasion: International Cooperation in the Refugee Regime
por: Betts, A
Publicado: (2010)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
por: Dean, G, et al.
Publicado: (2014)

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
por: Dicks, M, et al.
Publicado: (2012)

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
por: Vordermeier, H, et al.
Publicado: (2009)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado: (2009)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
por: White, A, et al.
Publicado: (2013)

Erratum: Viral booster vaccines improve mycobacterium bovis BCG-induced protection against bovine tuberculosis
por: Vordermeier, H, et al.
Publicado: (2011)

Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles
por: Tingfeng Wang, et al.
Publicado: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
por: Goonetilleke, N, et al.
Publicado: (2003)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
por: Stylianou, E, et al.
Publicado: (2019)

The Use of Viral Vectors for Gene Therapy and Vaccination in Tuberculosis
por: Dulce Mata-Espinosa, et al.
Publicado: (2023-10-01)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Brookes, R, et al.
Publicado: (2008)

Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector–Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats
por: Aigerim Mailybayeva, et al.
Publicado: (2020-02-01)